WHO Expert Committee on Drug Dependence. (2017) 39th Expert Committee on Drug Dependence: technical documents. Geneva: World Health Organization. Thirty-ninth meeting, Geneva, 6-10 November 2017.
External website: http://www.who.int/medicines/access/controlled-sub...
4. Critical reviews of psychoactive substances
4.1 AB-CHMINACA
- Critical Review Report pdf, 979kb
- Expert Peer Review No.1 pdf, 513kb Expert Peer Review No.2 pdf, 635kb
- Annex 1: Questionnaire Report pdf, 274kb
4.2 5F-ADB
- Critical Review Report pdf, 850kb
- Expert Peer Review No.1 pdf, 512kb Expert Peer Review No.2 pdf, 513kb
- Annex 1: Questionnaire Report pdf, 274kb
4.3 4-fluoroamphetamine (4-FA)
- Critical Review Report pdf, 1.29Mb
- Expert Peer Review No.1 pdf, 499kb Expert Peer Review No.2 pdf, 516kb
- Annex 1: Questionnaire Report pdf, 274kb
4.4 AB-PINACA
- Critical Review Report pdf, 1.11Mb
- Expert Peer Review No.1 pdf, 515kb Expert Peer Review No.2 pdf, 507kb
- Annex 1: Questionnaire Report pdf, 274kb
4.5 Ocfentanil
- Critical Review Report pdf, 655kb
- Expert Peer Review No.1 pdf, 502kb Expert Peer Review No.2 pdf, 399kb
- Annex 1: Questionnaire Report pdf, 411kb
4.6 Furanyl fentanyl (Fu-F)
- Critical Review Report pdf, 775kb
- Expert Peer Review No.1 pdf, 399kb Expert Peer Review No.2 pdf, 403kb
- Annex 1: Questionnaire Report pdf, 381kb
4.7 Acryloylfentanyl (Acrylfentanyl)
- Critical Review Report pdf, 973kb
- Expert Peer Review No.1 pdf, 399kb Expert Peer Review No.2 pdf, 363kb
- Annex 1: Questionnaire Report pdf, 272kb
4.8 Carfentanil
- Pre-Review Report pdf, 1.00Mb
- Expert Peer Review No.1 (Revised) pdf, 527kb Expert Peer Review No.2 (Revised) pdf, 519kb
- Annex 1: Questionnaire Report pdf, 273kb
4.9 4-fluoroisobutyrfentanyl (4-FIBF, pFIBF)
- Critical Review Report pdf, 961kb
- Expert Peer Review No.1 pdf, 400kb Expert Peer Review No.2 pdf, 400kb
- Annex 1: Questionnaire Report pdf, 378kb
4.10 Tetrahydrofuranylfentanyl (THF-F)
- Critical Review Report pdf, 947kb
- Expert Peer Review No.1 pdf, 515kb Expert Peer Review No.2 pdf, 400kb
- Annex 1: Questionnaire Report pdf, 271kb
4.11 UR-144
- Critical Review Report pdf, 993kb
- Expert Peer Review No.1 pdf, 372kb Expert Peer Review No.2 pdf, 517kb
- Annex 1: Questionnaire Report pdf, 410kb
4.12 5F-PB-22
- Critical Review Report pdf, 949kb
- Expert Peer Review No.1 pdf, 511kb Expert Peer Review No.2 pdf, 510kb
- Annex 1: Questionnaire Report pdf, 273kb
4.13 Etizolam
- Critical Review Report pdf, 942kb
- Expert Peer Review No.1 pdf, 508kb Expert Peer Review No.2 pdf, 593kb
- Annex 1: Questionnaire Report pdf, 273kb
5. Pre-reviews of substances
5.1 Pregabalin*
- Pre Review Report pdf, 1.24Mb
- Expert Peer Review No.1 pdf, 502kb Expert Peer Review No.2 pdf, 607kb
- Annex 1: Questionnaire Report pdf, 274kb
5.2 Cannabidiol*
- Pre Review Report pdf, 1.11Mb
- Expert Peer Review No.1 pdf, 402kb Expert Peer Review No.2 pdf, 531kb
- Annex 1: Questionnaire Report pdf, 273kb
5.3 Tramadol*
B Substances > Cannabis product (Cannabinoids)
B Substances > Cannabis product (Cannabinoids) > Cannabinol / Cannabidiol (CBD oil)
B Substances > New (novel) psychoactive substances
B Substances > New (novel) psychoactive substances > Benzodiazepines
B Substances > New (novel) psychoactive substances > Indolalkylamines (tryptamines) / Phenethylamines
B Substances > New (novel) psychoactive substances > Synthetic cannabinoids (Spice / K2 / OXIZID / HHC)
B Substances > New (novel) psychoactive substances > Synthetic opioids > Fentanyl, Fentanils
B Substances > New (novel) psychoactive substances > Other novel substances > Gabapentinoids GABA (Pregabalin / Gabapentin)
E Concepts in biomedical areas > Medical substance > Prescription drug (medicine / medication)
L Social psychology and related concepts > Legal availability or accessibility
MM-MO Crime and law > Substance use laws > Drug laws
VA Geographic area > International
Repository Staff Only: item control page